Want to see SE:SEZI full AI Analyst Report?
SEZI Stock Chart & Stats
kr5.13
-kr0.14(-2.60%)
At close: 4:00 PM EST
kr5.13
-kr0.14(-2.60%)
Day’s Range― - ―
52-Week Rangekr3.85 - kr7.38
Previous CloseN/A
Volume45.51K
Average Volume (3M)534.13K
Market Cap
kr666.59M
Enterprise Valuekr669.97M
Total Cash (Recent Filing)kr55.35M
Total Debt (Recent Filing)kr21.79M
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Jul 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.81
Shares Outstanding157,215,040
10 Day Avg. Volume328,516
30 Day Avg. Volume534,125
Financial Highlights & Ratios
PEG Ratio1.41
Price to Book (P/B)2.61
Price to Sales (P/S)7.63
P/FCF Ratio-7.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.2
Revenue Forecast (FY)kr176.30M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables GrowthSustained sensor-volume growth and a million monitored‑patient milestone indicate a durable recurring‑revenue base. Consumables drive gross‑margin leverage and predictable revenue streams as installed devices beget ongoing disposables demand, improving cash visibility as penetration grows.
Shift To TetraGraph-as-a-ServiceMoving from pure capital sales to an as‑a‑service model shortens sales cycles, accelerates deployments and ties more recurring consumable usage to installed units. This structural commercial change improves customer adoption, steadies revenue cadence, and can raise lifetime margins and retention.
Conservative Capital Structure And Available RunwayLow leverage and on‑balance cash plus unused credit provide flexibility to fund near‑term operations and execution while management works to hit cash‑flow positive targets. A conservative capital structure reduces short‑term refinancing risk while execution on growth continues.
Bears Say
Large Operating Cash BurnPersistent, large negative operating and free cash flow is a primary structural weakness. Ongoing cash burn forces reliance on balance‑sheet resources or external financing, constrains strategic investments, and raises dilution/refinancing risk unless sustained margin and sales improvements materialize.
Revenue DecelerationA marked revenue decline reverses earlier scale gains and undermines operating‑leverage benefits. With fixed costs and a high cost base, falling top line exacerbates losses and delays the path to break‑even, making operational execution and demand recovery critical for durable improvement.
Sales‑cycle And Regulatory Timing RiskDependence on hospital procurement and staggered regulatory approvals creates lumpy, timing‑sensitive revenue. Delays in key geographies or slow IDN rollouts can push sensor consumption and device sales into later periods, making forecasts and cash‑flow targets vulnerable to execution timing.
Senzime AB News
SEZI FAQ
What was Senzime AB’s price range in the past 12 months?
Senzime AB lowest stock price was kr3.85 and its highest was kr7.38 in the past 12 months.
What is Senzime AB’s market cap?
Senzime AB’s market cap is kr666.59M.
When is Senzime AB’s upcoming earnings report date?
Senzime AB’s upcoming earnings report date is Jul 16, 2026 which is in 12 days.
How were Senzime AB’s earnings last quarter?
Senzime AB released its earnings results on Apr 22, 2026. The company reported -kr0.143 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.143.
Is Senzime AB overvalued?
According to Wall Street analysts Senzime AB’s price is currently Overvalued.
Does Senzime AB pay dividends?
Senzime AB does not currently pay dividends.
What is Senzime AB’s EPS estimate?
Senzime AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Senzime AB have?
Senzime AB has 157,215,040 shares outstanding.
What happened to Senzime AB’s price movement after its last earnings report?
Senzime AB reported an EPS of -kr0.143 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -15.901%.
Which hedge fund is a major shareholder of Senzime AB?
Currently, no hedge funds are holding shares in SE:SEZI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Senzime AB
Senzime AB (publ) is a medical technology firm specializing in the creation and distribution of advanced patient monitoring solutions. These systems are designed to oversee patients undergoing anesthesia across various global markets, including Europe, Oceania, Asia, Canada, and the United States. Among its primary offerings is the TetraGraph, a sophisticated monitor designed to assess and display muscle function in surgical patients administered neuromuscular blocking agents, by stimulating, measuring, and analyzing responses. This system is complemented by the TetraSens electrode array, featuring two proximal stimulating electrodes for precise recording and reference. For data management, TetraConnect serves as a portal, allowing clinicians to conveniently access, view, and export TetraGraph data records in PDF or Excel formats. Furthermore, TetraGraph Device Connectivity facilitates the transfer of data from the TetraGraph Monitor to other patient monitoring systems, while the TetraGraph Philips Interface specifically enables the transmission of critical neuromuscular monitoring parameters—such as TOFC, TOFR, PTC, and TOF bars—to Philips patient monitors, with readings visible on the Philips Intellivue Monitor. Senzime is also actively developing the CliniSenz Analyzer, intended for continuous postoperative patient monitoring within hospital settings. Another innovation in its pipeline is the Onzurf Probe, a sterile, CE-marked single-use device leveraging micro-dialysis technology for continuous sampling from gastrointestinal organs, including the esophagus, stomach, and liver. The company maintains a strategic licensing and connectivity partnership with Masimo. This collaboration focuses on developing and commercializing the TetraGraph Smart Cable Module, designed to integrate seamlessly with Masimo's Root monitoring system and their digital hubs, thereby enabling interaction with hospital clinical information systems and electronic health records. Established in 1999, Senzime AB (publ) operates from its headquarters in Uppsala, Sweden.
SEZI Company Deck
SEZI Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally positive outlook: the company reported strong underlying operational momentum (notably sensor growth, a 1M monitored‑patient milestone, margin improvement, new business models like TetraGraph‑as‑a‑Service, TetraCom and important customer wins) while acknowledging a temporary Q1 growth dip driven by delayed U.S. deals, FX and tariff headwinds and some regional regulatory timing issues. Management emphasizes cost discipline, a solid pipeline, available funding and confidence in meeting full‑year objectives, but execution (recovering delayed deals, FX/tariff resolution and regulatory rollouts) is needed to realize targets.View all SE:SEZI earnings summariesTechnical Analysis
1 Day
3 Days
1 Week
1 Month
Bactiguard Holding AB
―
C-Rad AB Class B
―
Integrum AB Class B
―
Sedana Medical AB
―
OssDsign AB
―
Options Prices
Currently, No data available
---







